R & D Partners
Ontherix, Inc., Sunnyvale, CA.
Ontherix-Transporin Joint Development Program is focused on a
late-preclinical stage drug, Nephrilin(TM), a first-in-class inhibitor
of neuroinflammatory reactions to stress.
Molecular Medicine Research
Institute, Sunnyvale, CA.
and MMRI have partnered to develop and sell the Transfexa(TM) line of
research reagents through third-party vendors. These molecules allow
rapid, targeted and efficient delivery of nucleic acids into cells,
both in vivo and in vitro, without the use of lipid carriers. This
technology is potentially transformative for the fields of RNAi and
Goodwin Biotechnology, Inc.,
collaboration aims to sell novel solutions to clients whose
biopharmaceuticals are already utilizing the company's CMO services.
The transporter technology
may increase specificity of targeting in vivo, potentially
differentiating the company's offering within a highly competitive
Shriners Burn Unit, Galveston,
research collaboration has already generated novel insights into the
mechanisms of action of Nephrilin(TM) in the treatment of severe burns.
Some of this work is already published in peer-reviewed scientific
University of Mississipi,
collaborator is looking at the potential use of our technology in the
treatment of post-operative complications in heavy smokers.
Desmond Mascarenhas, Ph.D,
Mascarenhas owns three decades of experience in the technological
innovation industries. He has established a successful track record as
an entrepreneur, founding and operating ten corporate enterprises over
the past eighteen years. Bioexpertise, Inc., a physician education
company he founded in 2000 was recognized as an innovation leader in
its field. Its clients included 12 of the 15 largest pharmaceutical
companies. Mascarenhas has authored 30+ US patents and published dozens
of peer-reviewed research papers. He holds a doctorate from Oxford
University (which he attended as a Rhodes Scholar) and was a
Post-doctorate Fellow at Stanford University.